The team
About Us
AMiLion Technology was founded by Alesia Tietze and Daniel Tietze in 2021. Their recent achievements in the field of nanopore-based sensing technology platform has a great potential for analyte detection at unseen precision, sensitivity and speed.
AMiLion has drawn in an initial investment from GU Ventures and is part of their incubator program.
Prof. Alesia A. Tietze
WCMTM & CMB UGOT
Co-founder
Alesia is a Professor at the University of Gothenburg, at the Department of Chemistry and Molecular Biology and part of the Wallenberg Centre for Molecular and Translational Medicine. Alesia is leading a research group which focuses on bioinspired chemical engineering of peptide-based molecules/ materials towards diagnostics and drug delivery. Together with her research team she develops novel approaches with the goal of providing access to highly hydrophobic peptides/peptide mimetics, i.e. transmembrane peptides/proteins and venom-derived cysteine-rich peptides.
Dr. Daniel Tietze
WCMTM & CMB UGOT
Co-founder
Daniel is a researcher at the University of Gothenburg, at the Department of Chemistry and Molecular Biology and part of the Wallenberg Centre for Molecular and Translational Medicine. He is part of Alesia’s research team, supporting them with his expert knowledge in analytical chemsitry, NMR spectroscopy and theoretical chemistry.
Helena Lundquist
Buisness advisor
Helena is a Business Coach at GU Ventures. She has a degree from Handelshögskolan at Gothenburg University (Master of Science in Business Adm). Helena has recently joined GU ventures after working 25 years in big global pharmaceutical companies in various roles within commercial and governmental affairs. She has extensive experience within Life Science and good knowledge of the processes of bringing innovations to the health care market through market analysis and market access. She is member of several boards of start-up companies and chairman of the board of AMiLion from May 2023.